0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial | ONLINE FIRST

What Does Off-label Prescribing Really Mean?

Patrick G. O’Malley, MD, MPH
Arch Intern Med. 2012;172(10):759-760. doi:10.1001/archinternmed.2012.789.
Text Size: A A A
Published online

Extract

The issue of off-label prescribing is a loaded subject. When one scratches the surface, one realizes the myriad limitations of such a construct related to the process of labeling, the monitoring of appropriate prescribing, the inadequacy of evidence to match the complexities of care, and the missed opportunities of leveraging our information systems to better optimize medication use for the care of patients.

Technically, off-label prescribing means the prescribing of medications or devices for indications or population subgroups that regulatory agencies have not officially approved. It is legal in many countries (including the United States) based on the premise that regulatory agencies do not have the authority to control the practice of medicine. But what does it really mean? There are many examples of efficacious medical therapies for conditions for which there has been no official indication approval. Aspirin therapy for acute coronary syndromes is a classic example: regulatory approval for its use did not occur until well after the evidence clearly demonstrated its benefit. The process of drug approval for specific indications is an onerous one, requiring substantial resources and financial risk to seek labeling indications. Even if there are available studies that demonstrate efficacy, the burden of indication application is on the pharmaceutical company. Unless there is reasonable probability for profit margins associated with such investment, the pharmaceutical industry is not likely to seek regulatory approval. Therefore, there is an obvious limitation of the process of labeling that inhibits not only the potential access to efficacious treatments but also the validity of labeling itself. A better process would allow an easier updating of indication labeling that is concordant and commensurate with the strength of the evidence.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();